Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors

US8987301B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Alfred Jonczyk · Darmstadt, DE
• Christiane Amendt · Mühltal, DE
• Frank Zenke · Darmstadt, DE

Key dates

• Filing date: Oct 12, 2010
• Grant date: Mar 24, 2015
• Expiry date: Oct 24, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel hetarylaminoquinoline derivatives of formula (I)wherein X, Z, Het, R1, R2, R3 and R4 have the meaning according to claim 1, are inhibitors of ATP consuming proteins, and can be employed, inter alia, for the treatment of tumors.